Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:41:36.892Z.
Calculation as of: 2026-10-06T13:41:36.892Z.
Quote observation: 2026-10-06T13:40:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d42caa3e816b0495fa2340ecfe28e9cd39b3fd8bb52e96b9f838481ccca068c7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$339.93M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$311.25M
EV/EBITDA Ratio
N/A
TTM Avg
22.81x
3Y Avg
22.81x
5Y Avg
22.81x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $329.49M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $334.26M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $318.27M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $339.93M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $350.42M | 9.10x | 20.16x | 20.16x | 12.62x |
| Embecta Corp. (EMBC)vs › | $348.85M | 5.36x | 4.73x | 7.57x | 7.31x |
| Benitec Biopharma Inc. (BNTC)vs › | $311.25M | N/A | 22.81x | 22.81x | 22.81x |
| ClearPoint Neuro, Inc. (CLPT)vs › | $348.63M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $305.38M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $359.16M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
